Movement Alert｜Caris Life Sciences Rises 5.07% in Regular Trading, BofA Raises Price Target to $35 Boosting Precision Medicine Sentiment

Market Focus10-09

On October 9, Caris Life Sciences, Inc. rose 5.07% in regular trading, trading at $28.895 per share with turnover of $7.8659 million. The rally was driven by BofA Securities raising its price target on the stock to $35 from $23, reinforcing confidence in the company's AI-driven precision oncology platform.

The upward revision follows Caris's second-quarter revenue of $263.7 million, which beat the consensus estimate of $238.1 million. Recent product developments, including the launch of its PTEN IHC test for metastatic prostate cancer and MolDx approval for Caris Chromoseq, have further strengthened the company's position in precision medicine. Within the biotechnology sector, Moderna gained 8.59%, Twist Bioscience rose 8.8%, Natera advanced 3.7%, AbbVie added 1.14%, and Amgen edged up 1.13%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment